TELA BIO INC (TELA)
US8723811084 - Common Stock
Overall TELA gets a fundamental rating of 3 out of 10. We evaluated TELA against 193 industry peers in the Health Care Equipment & Supplies industry. TELA may be in some trouble as it scores bad on both profitability and health. TELA is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
TELA had negative earnings in the past year.
In the past year TELA has reported a negative cash flow from operations.
In the past 5 years TELA always reported negative net income.
TELA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
TELA's Return On Assets of -59.80% is on the low side compared to the rest of the industry. TELA is outperformed by 73.58% of its industry peers.
TELA's Return On Equity of -247.18% is on the low side compared to the rest of the industry. TELA is outperformed by 81.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -59.8% | ||
| ROE | -247.18% | ||
| ROIC | N/A |
ROA(3y)-59.43%
ROA(5y)-51.21%
ROE(3y)-240.76%
ROE(5y)-175.72%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TELA has a Gross Margin of 68.63%. This is in the better half of the industry: TELA outperforms 76.17% of its industry peers.
In the last couple of years the Gross Margin of TELA has grown nicely.
TELA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.63% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.63%
GM growth 5Y14.06%
2. Health
2.1 Basic Checks
TELA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TELA has more shares outstanding
TELA has more shares outstanding than it did 5 years ago.
The debt/assets ratio for TELA has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -4.57, we must say that TELA is in the distress zone and has some risk of bankruptcy.
TELA has a worse Altman-Z score (-4.57) than 67.36% of its industry peers.
TELA has a Debt/Equity ratio of 2.15. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 2.15, TELA is not doing good in the industry: 83.94% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.15 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.57 |
ROIC/WACCN/A
WACC10.34%
2.3 Liquidity
TELA has a Current Ratio of 4.23. This indicates that TELA is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of TELA (4.23) is better than 63.21% of its industry peers.
A Quick Ratio of 3.45 indicates that TELA has no problem at all paying its short term obligations.
With a decent Quick ratio value of 3.45, TELA is doing good in the industry, outperforming 64.77% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.23 | ||
| Quick Ratio | 3.45 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 23.33% over the past year.
TELA shows a strong growth in Revenue. In the last year, the Revenue has grown by 41.11%.
TELA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 47.86% yearly.
EPS 1Y (TTM)23.33%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-1.92%
Revenue 1Y (TTM)41.11%
Revenue growth 3Y47.51%
Revenue growth 5Y47.86%
Revenue growth Q2Q46.28%
3.2 Future
Based on estimates for the next years, TELA will show a very strong growth in Earnings Per Share. The EPS will grow by 22.94% on average per year.
TELA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 28.64% yearly.
EPS Next Y14.12%
EPS Next 2Y17.71%
EPS Next 3Y17.42%
EPS Next 5Y22.94%
Revenue Next Year29.37%
Revenue Next 2Y27.3%
Revenue Next 3Y26.8%
Revenue Next 5Y28.64%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for TELA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TELA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
TELA's earnings are expected to grow with 17.42% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.71%
EPS Next 3Y17.42%
5. Dividend
5.1 Amount
TELA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TELA BIO INC
NASDAQ:TELA (5/15/2024, 7:11:46 PM)
After market: 5.98 0 (0%)5.98
+0.16 (+2.75%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap147.41M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -59.8% | ||
| ROE | -247.18% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.63% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.75
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.15 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.23 | ||
| Quick Ratio | 3.45 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)23.33%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y14.12%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)41.11%
Revenue growth 3Y47.51%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y